Abstract
Background. Lynch syndrome is the most common genetic predisposition for hereditary cancer. Carriers of pathogenic changes in mismatch repair (MMR) genes have an increased risk of developing colorectal (CRC), endometrial, ovarian, urinary tract, prostate, and other cancers, depending on which gene is malfunctioning. In Lynch syndrome, differences in cancer incidence (penetrance) according to the gene involved have led to the stratification of cancer surveillance. By contrast, any differences in penetrance determined by the type of pathogenic variant remain unknown. Objective. To determine cumulative incidences of cancer in carriers of truncating and missense or aberrant splicing pathogenic variants of the MLH1 and MSH2 genes. Methods. Carriers of pathogenic variants of MLH1 (path_MLH1) and MSH2 (path_MSH2) genes filed in the Prospective Lynch Syndrome Database (PLSD) were categorized as truncating or missense/aberrant splicing according to the InSiGHT criteria for pathogenicity. Results. Among 5199 carriers, 1045 had missense or aberrant splicing variants, and 3930 had truncating variants. Prospective observation years for the two groups were 8205 and 34,141 years, respectively, after which there were no significant differences in incidences for cancer overall or for colorectal cancer or endometrial cancers separately. Conclusion. Truncating and missense or aberrant splicing pathogenic variants were associated with similar average cumulative incidences of cancer in carriers of path MLH1 and path_MSH2.
Original language | English |
---|---|
Article number | 2856 |
Journal | Journal of Clinical Medicine |
Volume | 10 |
Issue number | 13 |
Number of pages | 12 |
ISSN | 2077-0383 |
DOIs | |
Publication status | Published - 2021 |
Externally published | Yes |
Keywords
- Aberrant splicing
- Cancer incidence
- Lynch syndrome
- Missense
- MLH1
- MSH2
- Penetrance
- Truncating
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
No difference in penetrance between truncating and missense/aberrant splicing pathogenic variants in mlh1 and msh2 : A prospective lynch syndrome database study. / Dominguez-Valentin, Mev; Plazzer, John Paul; Sampson, Julian R.; Engel, Christoph; Aretz, Stefan; Jenkins, Mark A.; Sunde, Lone; Bernstein, Inge; Capella, Gabriel; Balaguer, Francesc; Macrae, Finlay; Winship, Ingrid M.; Thomas, Huw; Evans, Dafydd Gareth; Burn, John; Greenblatt, Marc; de Vos tot Nederveen Cappel, Wouter H.; Sijmons, Rolf H.; Nielsen, Maartje; Bertario, Lucio; Bonanni, Bernardo; Tibiletti, Maria Grazia; Cavestro, Giulia Martina; Lindblom, Annika; Della Valle, Adriana; Lopez-Kostner, Francisco; Alvarez, Karin; Gluck, Nathan; Katz, Lior; Heinimann, Karl; Vaccaro, Carlos A.; Nakken, Sigve; Hovig, Eivind; Green, Kate; Lalloo, Fiona; Hill, James; Vasen, Hans F.A.; Perne, Claudia; Büttner, Reinhard; Görgens, Heike; Holinski-Feder, Elke; Morak, Monika; Holzapfel, Stefanie; Hüneburg, Robert; Doeberitz, Magnus von Knebel; Loeffler, Markus; Rahner, Nils; Weitz, Jürgen; Steinke-Lange, Verena; Schmiegel, Wolff; Vangala, Deepak; Crosbie, Emma J.; Pineda, Marta; Navarro, Matilde; Brunet, Joan; Moreira, Leticia; Sánchez, Ariadna; Serra-Burriel, Miquel; Mints, Miriam; Kariv, Revital; Rosner, Guy; Piñero, Tamara Alejandra; Pavicic, Walter Hernán; Kalfayan, Pablo; Ten Broeke, Sanne W.; Mecklin, Jukka Pekka; Pylvänäinen, Kirsi; Renkonen-Sinisalo, Laura; Lepistö, Anna; Peltomäki, Päivi; Hopper, John L.; Win, Aung Ko; Buchanan, Daniel D.; Lindor, Noralane M.; Gallinger, Steven; Marchand, Loïc Le; Newcomb, Polly A.; Figueiredo, Jane C.; Thibodeau, Stephen N.; Therkildsen, Christina; Hansen, Thomas V.O.; Lindberg, Lars; Rødland, Einar Andreas; Neffa, Florencia; Esperon, Patricia; Tjandra, Douglas; Möslein, Gabriela; Seppälä, Toni T.; Møller, Pål.
In: Journal of Clinical Medicine, Vol. 10, No. 13, 2856, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
}
TY - JOUR
T1 - No difference in penetrance between truncating and missense/aberrant splicing pathogenic variants in mlh1 and msh2
T2 - A prospective lynch syndrome database study
AU - Dominguez-Valentin, Mev
AU - Plazzer, John Paul
AU - Sampson, Julian R.
AU - Engel, Christoph
AU - Aretz, Stefan
AU - Jenkins, Mark A.
AU - Sunde, Lone
AU - Bernstein, Inge
AU - Capella, Gabriel
AU - Balaguer, Francesc
AU - Macrae, Finlay
AU - Winship, Ingrid M.
AU - Thomas, Huw
AU - Evans, Dafydd Gareth
AU - Burn, John
AU - Greenblatt, Marc
AU - de Vos tot Nederveen Cappel, Wouter H.
AU - Sijmons, Rolf H.
AU - Nielsen, Maartje
AU - Bertario, Lucio
AU - Bonanni, Bernardo
AU - Tibiletti, Maria Grazia
AU - Cavestro, Giulia Martina
AU - Lindblom, Annika
AU - Della Valle, Adriana
AU - Lopez-Kostner, Francisco
AU - Alvarez, Karin
AU - Gluck, Nathan
AU - Katz, Lior
AU - Heinimann, Karl
AU - Vaccaro, Carlos A.
AU - Nakken, Sigve
AU - Hovig, Eivind
AU - Green, Kate
AU - Lalloo, Fiona
AU - Hill, James
AU - Vasen, Hans F.A.
AU - Perne, Claudia
AU - Büttner, Reinhard
AU - Görgens, Heike
AU - Holinski-Feder, Elke
AU - Morak, Monika
AU - Holzapfel, Stefanie
AU - Hüneburg, Robert
AU - Doeberitz, Magnus von Knebel
AU - Loeffler, Markus
AU - Rahner, Nils
AU - Weitz, Jürgen
AU - Steinke-Lange, Verena
AU - Schmiegel, Wolff
AU - Vangala, Deepak
AU - Crosbie, Emma J.
AU - Pineda, Marta
AU - Navarro, Matilde
AU - Brunet, Joan
AU - Moreira, Leticia
AU - Sánchez, Ariadna
AU - Serra-Burriel, Miquel
AU - Mints, Miriam
AU - Kariv, Revital
AU - Rosner, Guy
AU - Piñero, Tamara Alejandra
AU - Pavicic, Walter Hernán
AU - Kalfayan, Pablo
AU - Ten Broeke, Sanne W.
AU - Mecklin, Jukka Pekka
AU - Pylvänäinen, Kirsi
AU - Renkonen-Sinisalo, Laura
AU - Lepistö, Anna
AU - Peltomäki, Päivi
AU - Hopper, John L.
AU - Win, Aung Ko
AU - Buchanan, Daniel D.
AU - Lindor, Noralane M.
AU - Gallinger, Steven
AU - Marchand, Loïc Le
AU - Newcomb, Polly A.
AU - Figueiredo, Jane C.
AU - Thibodeau, Stephen N.
AU - Therkildsen, Christina
AU - Hansen, Thomas V.O.
AU - Lindberg, Lars
AU - Rødland, Einar Andreas
AU - Neffa, Florencia
AU - Esperon, Patricia
AU - Tjandra, Douglas
AU - Möslein, Gabriela
AU - Seppälä, Toni T.
AU - Møller, Pål
N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - Background. Lynch syndrome is the most common genetic predisposition for hereditary cancer. Carriers of pathogenic changes in mismatch repair (MMR) genes have an increased risk of developing colorectal (CRC), endometrial, ovarian, urinary tract, prostate, and other cancers, depending on which gene is malfunctioning. In Lynch syndrome, differences in cancer incidence (penetrance) according to the gene involved have led to the stratification of cancer surveillance. By contrast, any differences in penetrance determined by the type of pathogenic variant remain unknown. Objective. To determine cumulative incidences of cancer in carriers of truncating and missense or aberrant splicing pathogenic variants of the MLH1 and MSH2 genes. Methods. Carriers of pathogenic variants of MLH1 (path_MLH1) and MSH2 (path_MSH2) genes filed in the Prospective Lynch Syndrome Database (PLSD) were categorized as truncating or missense/aberrant splicing according to the InSiGHT criteria for pathogenicity. Results. Among 5199 carriers, 1045 had missense or aberrant splicing variants, and 3930 had truncating variants. Prospective observation years for the two groups were 8205 and 34,141 years, respectively, after which there were no significant differences in incidences for cancer overall or for colorectal cancer or endometrial cancers separately. Conclusion. Truncating and missense or aberrant splicing pathogenic variants were associated with similar average cumulative incidences of cancer in carriers of path MLH1 and path_MSH2.
AB - Background. Lynch syndrome is the most common genetic predisposition for hereditary cancer. Carriers of pathogenic changes in mismatch repair (MMR) genes have an increased risk of developing colorectal (CRC), endometrial, ovarian, urinary tract, prostate, and other cancers, depending on which gene is malfunctioning. In Lynch syndrome, differences in cancer incidence (penetrance) according to the gene involved have led to the stratification of cancer surveillance. By contrast, any differences in penetrance determined by the type of pathogenic variant remain unknown. Objective. To determine cumulative incidences of cancer in carriers of truncating and missense or aberrant splicing pathogenic variants of the MLH1 and MSH2 genes. Methods. Carriers of pathogenic variants of MLH1 (path_MLH1) and MSH2 (path_MSH2) genes filed in the Prospective Lynch Syndrome Database (PLSD) were categorized as truncating or missense/aberrant splicing according to the InSiGHT criteria for pathogenicity. Results. Among 5199 carriers, 1045 had missense or aberrant splicing variants, and 3930 had truncating variants. Prospective observation years for the two groups were 8205 and 34,141 years, respectively, after which there were no significant differences in incidences for cancer overall or for colorectal cancer or endometrial cancers separately. Conclusion. Truncating and missense or aberrant splicing pathogenic variants were associated with similar average cumulative incidences of cancer in carriers of path MLH1 and path_MSH2.
KW - Aberrant splicing
KW - Cancer incidence
KW - Lynch syndrome
KW - Missense
KW - MLH1
KW - MSH2
KW - Penetrance
KW - Truncating
U2 - 10.3390/jcm10132856
DO - 10.3390/jcm10132856
M3 - Journal article
C2 - 34203177
AN - SCOPUS:85114073501
VL - 10
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
SN - 2077-0383
IS - 13
M1 - 2856
ER -